相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection
Wen-Juan Tian et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum
John H. Farley et al.
CANCER RESEARCH (2012)
The Changing View of High-Grade Serous Ovarian Cancer
Els M. J. J. Berns et al.
CANCER RESEARCH (2012)
Targeting angiogenesis in ovarian cancer
Jordan Schmitt et al.
CANCER TREATMENT REVIEWS (2012)
Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Bradley J. Monk et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)
Dennis S. Chi et al.
GYNECOLOGIC ONCOLOGY (2012)
Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer
Andreas du Bois et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Moving Beyond Anti-Vascular Endothelial Growth Factor Therapy in Ovarian Cancer
Anil K. Sood et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.
Ignace B. Vergote et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Stan B. Kaye et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
Justin N. Bottsford-Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries
Lydia Kapiriri et al.
BMC PUBLIC HEALTH (2011)
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
R. Y. Zang et al.
BRITISH JOURNAL OF CANCER (2011)
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
C. K. Lee et al.
BRITISH JOURNAL OF CANCER (2011)
Cotargeting of VEGFR-1 and-3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice
H. Sallinen et al.
CANCER GENE THERAPY (2011)
Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma
Rong Wu et al.
CLINICAL CANCER RESEARCH (2011)
Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer
R. Wendel Naumann et al.
DRUGS (2011)
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2011)
CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer
Nicole D. Fleming et al.
GYNECOLOGIC ONCOLOGY (2011)
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Philipp Harter et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Da Yang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Neoadjuvant Chemotherapy Is the Better Treatment Option in Some Patients With Stage IIIc to IV Ovarian Cancer
Ignace Vergote et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Personalized cancer medicine-advances and socio-economic challenges
David B. Jackson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
RNA interference in the clinic: challenges and future directions
Chad V. Pecot et al.
NATURE REVIEWS CANCER (2011)
Rethinking ovarian cancer: recommendations for improving outcomes
Sebastian Vaughan et al.
NATURE REVIEWS CANCER (2011)
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Maintenance Chemotherapy: An Evolving and Increasingly Acceptable Strategy in Cancer Management
Maurie Markman
CURRENT ONCOLOGY REPORTS (2010)
The genesis and evolution of high-grade serous ovarian cancer
David D. L. Bowtell
NATURE REVIEWS CANCER (2010)
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuan-Ting Kuo et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois et al.
CANCER (2009)
Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas
Kuan-Ting Kuo et al.
CANCER RESEARCH (2009)
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
David M. Gershenson et al.
GYNECOLOGIC ONCOLOGY (2009)
Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer From Platinum Doublets to Nonplatinum Doublets and Adding Antiangiogenesis Compounds
Bradley J. Monk et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
David S. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Noriyuki Katsumata et al.
LANCET (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation
Katsutoshi Oda et al.
CANCER RESEARCH (2008)
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
Richard W. Tothill et al.
CLINICAL CANCER RESEARCH (2008)
The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer
Eric L. Eisenhauer et al.
GYNECOLOGIC ONCOLOGY (2008)
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
Gabriella Ferrandina et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Role of surgery in ovarian carcinoma
Amanda Nickles Fader et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer
Pierluigi Benedetti Panici et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Y. Lee et al.
JOURNAL OF PATHOLOGY (2007)
Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma
D. de Jong et al.
ONCOLOGY (2007)
Surgery in recurrent ovarian cancer:: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
Philipp Harter et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis
Robert E. Bristow et al.
GYNECOLOGIC ONCOLOGY (2006)
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group
Cheryl A. Brewer et al.
GYNECOLOGIC ONCOLOGY (2006)
Ovarian cancer: a focus on management of recurrent disease
Thomas J. Herzog et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The role of maintenance therapy and novel taxanes in ovarian cancer
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2006)
Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients
Arturas Inciura et al.
BMC CANCER (2006)
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:: A Gynecologic Oncology Group study
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2006)
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma
DS Chi et al.
CANCER (2006)
Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery
SJ Lee et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer
H Steed et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: A non-randomized comparison using an explanatory analysis: A Gynecologic Oncology Group study
BE Greer et al.
GYNECOLOGIC ONCOLOGY (2005)
Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer
T Le et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad
KA Strait et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer
K Hata et al.
GYNECOLOGIC ONCOLOGY (2004)
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
AN Gordon et al.
GYNECOLOGIC ONCOLOGY (2004)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
A du Bois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2003)
Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: Invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor)
G Singer et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2003)
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum
P Rosenberg et al.
ACTA ONCOLOGICA (2002)
Neoadjuvant chemotherapy for the management of ovarian cancer
PE Schwartz
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2002)
Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen
R Jelliffe
AMERICAN JOURNAL OF NEPHROLOGY (2002)
Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
EH Tay et al.
OBSTETRICS AND GYNECOLOGY (2002)
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
RE Bristow et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
MJ Piccart et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
MJ Piccart et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
